

GEOVAX LABS, INC.
Condensed Consolidated Statements of Operations Information
(amounts in thousands, except common share information)

	Three Months Ended March 31,	
	2021	2020
Grant and collaboration revenues	\$ 110	\$ 716
Operating expenses:		
Research and development	603	809
General and administrative	1,071	502
	1,674	1,311
Loss from operations	(1,564)	(595)
Other income (expense), net	1	(1)
Net loss	\$ (1,563)	\$ (596)
Net loss per common share	\$ (0.29)	\$ (2.54)
Weighted average common shares outstanding	5,332,058	234,395

Condensed Consolidated Balance Sheet Information
(amounts in thousands, except common share information)

	March 31, 2021	Dec. 31, 2020
Assets:		
Cash and cash equivalents	\$ 20,843	\$ 9,884
Other current assets	118	351
Total current assets	20,961	10,235
Property and other assets, net	154	159
Total assets	\$ 21,115	\$ 10,394
Liabilities and stockholders' equity		
Total liabilities	\$ 464	\$ 825
Stockholders' equity	20,651	9,569
Total liabilities and stockholders' equity	\$ 21,115	\$ 10,394
Common shares outstanding	6,315,467	3,834,095